`By:
`Jane M. Love, Ph.D., Reg. No. 42,812
`Robert W. Trenchard
`GIBSON, DUNN & CRUTCHER LLP
`jlove@gibsondunn.com
`rtrenchard@gibsondunn.com
`Tel.: 212-351-3922
`Fax: 212-351-6322
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`v.
`NOVARTIS A.G.,
`Patent Owner.
`
`Case IPR2017-01550
`Patent 9,187,405
`
`
`
`
`
`NOVARTIS’ MOTION FOR ADMISSION PRO HAC VICE OF
`ROBERT W. TRENCHARD
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`Case No. IPR2017-01550
`Patent No. 9,187,405
`
`Statement of Precise Relief Requested
`Novartis AG (“Novartis”) hereby respectfully requests that the Patent Trial
`
`and Appeal Board (the “Board”) admit Robert W. Trenchard pro hac vice in this
`
`proceeding under 37 C.F.R. § 42.10(c). Good cause exists for the Board to grant
`
`Novartis’s motion.
`
`II.
`
`Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`Under 37 C.F.R. § 42.10(c), the Board may admit counsel pro hac vice for
`
`good cause, so long as lead counsel is a registered practitioner and subject to any
`
`other conditions the Board requires. Under Section 42.10(c), good cause includes
`
`when “counsel is an experienced litigating attorney and has an established
`
`familiarity with the subject matter at issue in the proceeding.”
`
`This application satisfies the requirements of Section 42.10(c):
`
`1.
`
`Lead counsel, Jane M. Love, Ph.D., the undersigned, is a registered
`
`practitioner.
`
`2. Mr. Trenchard is an experienced litigator and has an established
`
`familiarity with the subject matter at issue here, as shown in his accompanying June
`
`29, 2017 Declaration (“Trenchard Decl.”), Ex. 2001. That declaration shows that
`
`Mr. Trenchard has been a litigator for 22 years. He is a member in good standing of
`
`the New York and New Jersey State Bars, and is also admitted in several federal
`
`
`
`2
`
`
`
`
`
`
`courts. He is familiar with the subject matter of this case, including U.S. Pat. No.
`
`Case No. IPR2017-01550
`Patent No. 9,187,405
`
`9,187,405 (“the ‘405 patent”), the patent’s prosecution history, the underlying
`
`technology, and the prior art cited by the petitioner in this matter. Trenchard Decl.
`
`¶¶ 9-10 (Ex. 2001).
`
`3.
`
`In his declaration, Mr. Trenchard also attests to each of the listed items
`
`required by the Order – Authorizing Motion for Pro Hac Vice Admission – 37 C.F.R.
`
`§ 42.10 in IPR2013-00639. See Trenchard Decl. ¶¶ 1-13 (Ex. 2001).
`
`III. Conclusion
`For the foregoing reasons, Novartis respectfully requests that the Board admit
`
`Robert W. Trenchard pro hac vice in this proceeding.
`
`Respectfully Submitted,
`/Jane M. Love, Ph.D./
`Jane M. Love, Ph.D.
`Registration No. 42,812
`GIBSON, DUNN & CRUTCHER LLP
`200 Park Avenue
`New York, NY 10166
`Jlove@gibsondunn.com
`Tel.: 212-351-3922
`Fax: 212-230-8888
`Dated: June 29, 2017
`
`
`
`3
`
`
`
`
`
`
`Certificate of Service
`The undersigned certifies she did cause to be served true and correct copies of the
`
`Case No. IPR2017-01550
`Patent No. 9,187,405
`
`following:
`
`
`
`
`
`Novartis’ Motion for Admission for Robert W. Trenchard Pro Hac Vice
`
`Declaration of Robert W. Trenchard in Support of Motion for
`
`Admission Pro Hac Vice (Exhibit 2001)
`
`to be served via email on the following attorneys for Petitioner:
`
`Teresa Stanek Rea: TRea@Crowell.com
`Deborah H. Yellin: DYellin@Crowell.com
`Shannon M. Lentz: SLentz@Crowell.com
`
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Ave, NW
`Washington, DC 20004-2595
`Telephone: (202) 624-2500
`
`Tyler C. Liu: TLiu@agpharm.com
`
`Argentum Pharmaceuticals, LLC
`Telephone: (202) 749-8605
`
`Dated: June 29, 2017
`
`/Jane M. Love, Ph.D./
`Jane M. Love, Ph.D.
`Reg. No. 42,812
`Lead Counsel for Patent Owners
`
`
`
`
`
`
`
`